Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
Autor: | Jing Bo Liang, Jing Tang, Xiaobing Li, De Wu, Xu Yong Li, Li Peng |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Oncology Male Cancer Research Lung Neoplasms Pyridines medicine.medical_treatment chemistry.chemical_compound Antiangiogenesis therapy 0302 clinical medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Apatinib Molecular Targeted Therapy Neoplasm Metastasis General Medicine Middle Aged Rash Magnetic Resonance Imaging Pemetrexed Treatment Outcome Docetaxel 030220 oncology & carcinogenesis Adenocarcinoma Female medicine.symptom medicine.drug medicine.medical_specialty Non-small cell lung cancer (NSCLC) Cytotoxic chemotherapy Article 03 medical and health sciences Internal medicine medicine Biomarkers Tumor Humans Protein Kinase Inhibitors Aged Neoplasm Staging Chemotherapy Performance status business.industry medicine.disease Survival Analysis 030104 developmental biology chemistry Neoplasm Grading business Tomography X-Ray Computed Progressive disease |
Zdroj: | Oncology Research |
ISSN: | 1555-3906 0965-0407 |
Popis: | Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel in advanced NSCLC. We treated a total of 20 patients with metastatic NSCLC adenocarcinoma with apatinib in combination with either pemetrexed or docetaxel from January 2016 to March 2017. The performance status of these patients was 0 or 1. All of these patients had been previously treated with two or more lines of treatment and had experienced disease progression prior to study enrollment. The overall objective response rate (ORR) was 30%, with 6 patients who had partial response (PR), 10 patients who had stable disease (SD), and 4 patients who had progressive disease (PD). The main adverse events were skin rash, hypertension, palmar‐plantar erythrodysesthesia syndrome, diarrhea, and fatigue. Nearly 30% of patients required interruption of treatment as a result of toxicity. Our study demonstrated that apatinib combined with systemic cytotoxic chemotherapy has clinical efficacy in patients with disease-refractory metastatic NSCLC and provides evidence for further studies investigating apatinib-based combination regimens. |
Databáze: | OpenAIRE |
Externí odkaz: |